FDA Clears World’s First mRNA Flu Vaccine for Older Adults
U.S. health officials have greenlit mFlusiva, Moderna’s new mRNA-based seasonal flu vaccine for adults aged 50 and older. Built using the same breakthrough technology utilized during the COVID-19 pandemic, this shot provides a faster, more adaptable alternative to traditional vaccines.
With thousands of influenza-related deaths reported each year, this new option arrives just in time for the upcoming fall vaccination wave, with select pharmacies set to receive initial stock soon.
Key Highlights on the FDA Approval:
- 🎯 Full Approval (Ages 50–64): Backed by a 40,000-person clinical trial, mFlusiva proved 27% more effective at preventing the flu than a leading standard flu vaccine.
- ⚡ Accelerated Approval (Ages 65+): Granted based on strong antibody responses comparable to current high-dose senior shots, while Moderna completes a final follow-up study.
- 🛡️ Safety & Side Effects: No major safety concerns were reported. Common temporary reactions included arm pain, fever, fatigue, headaches, and body aches, occurring at a slightly higher rate than conventional flu